Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients

Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients

Bibliographic Details
Main Authors:	López-Cortés, Luis F., Ruiz-Valderas, Rosa, Jimenez-Jimenez, Luis, González-Escribano, María F., Torres-Cornejo, Almudena, Mata, Rosario, Rivero, Antonio, Pineda, Juan A., Marquez-Solero, Manuel, Viciana, Pompeyo
Format:	Online
Language:	English
Published:	Public Library of Science 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250391/

Similar Items

HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients
by: Rivero-Juarez, Antonio, et al.
Published: (2014)

Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy
by: BenMarzouk-Hidalgo, Omar J., et al.
Published: (2015)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
by: Gutierrez-Valencia, Alicia, et al.
Published: (2015)

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
by: Rivero-Juárez, Antonio, et al.
Published: (2012)

Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients
by: Corchado, Sara, et al.
Published: (2014)

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment
by: Menard, Amélie, et al.
Published: (2012)

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
by: Merchante, Nicolás, et al.
Published: (2015)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
by: Sandoughdaran, Saleh, et al.
Published: (2015)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
by: Macías, Juan, et al.
Published: (2015)

Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin
by: Sadeq, Refat, et al.
Published: (2013)

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin
by: Fujino, Tatsuya, et al.
Published: (2011)

Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial
by: Yan Xu, et al.
Published: (2017-08-01)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
by: Neukam, Karin, et al.
Published: (2015)

Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy
by: Nguyen, Truong Tam, et al.
Published: (2016)

Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome
by: Aldámiz-Echevarría, Teresa, et al.
Published: (2016)

Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients
by: Murata, Kazumoto, et al.
Published: (2013)

IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients
by: Bertol, Bruna C., et al.
Published: (2015)

Tango with the Gringo: the Hard Peg and Real Misalignment in Argentina
by: Alberola, Enrique, et al.
Published: (2013)

Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010
by: de Felipe, Beatriz, et al.
Published: (2011)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
by: Macías, J, et al.
Published: (2010)

The Complication of Coinfection
by: Pasman, Lesley
Published: (2012)

Pulmonary Tuberculosis and Lepromatous Leprosy Coinfection
by: Sendrasoa, F. A., et al.
Published: (2015)

Test of IL28B Polymorphisms in Chronic Hepatitis C Patients Treated with PegIFN and Ribavirin Depends on HCV Genotypes: Results from a Meta-Analysis
by: Jia, Zhifang, et al.
Published: (2012)

The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients
by: Bokharaei-Salim, Farah, et al.
Published: (2016)

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C
by: Markova, Antoaneta A., et al.
Published: (2014)

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study
by: Atsukawa, Masanori, et al.
Published: (2013)

The Change of Quantitative of HBeAg Can Predict the Efficacy of Peg-IFN-α 2a in HBeAgpositive CHB Patients
by: Ji Yong-jian, et al.
Published: (2013-09-01)

Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy
by: Holysz, M., et al.
Published: (2015)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
by: Zhang, Yu, et al.
Published: (2016)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
by: Bagaglio, Sabrina, et al.
Published: (2015)

Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4
by: Rizk, Hanan H., et al.
Published: (2016)

A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy
by: Laouénan, C, et al.
Published: (2015)

No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV
by: Fernández-Montero, JV, et al.
Published: (2010)

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes
by: González-de-Olano, David, et al.
Published: (2016)

The Peg Formboards
by: Wallin, J. E. Wallace
Published: (1918)

The square pegs
by: Krystyna, Weinstein
Published: (1973)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
by: López-Cortés, Luis F., et al.
Published: (2016)

Efficient Polyethylene Glycol (PEG) Mediated Transformation of the Moss Physcomitrella patens
by: Liu, Yen-Chun, et al.
Published: (2011)

The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C
by: Behnava, Bita, et al.
Published: (2016)

The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients
by: Núñez-Torres, Rocío, et al.
Published: (2016)